CAH SEC Filings

Cardinal Health Inc. reported strong performance for the second quarter of fiscal year 2026, driven by significant revenue growth and improved operating earnings. Total revenue increased by 19% year-over-year to $65.6 billion, fueled by robust sales in the Pharmaceutical and Specialty Solutions (Pharma) segment, primarily from branded and specialty pharmaceutical products and new customer acquisitions. The company also saw substantial growth in its Other segment, largely due to the acquisition of Advanced Diabetes Supply Group (ADS) and performance in OptiFreight® Logistics. Profitability also showed a marked improvement. GAAP operating earnings rose 29% to $707 million, while non-GAAP operating earnings saw a stronger 38% increase to $877 million. This growth was attributed to strategic acquisitions, including Solaris Health, and increased contributions from specialty pharmaceuticals and existing customers in the GMPD segment. Diluted EPS also followed this positive trend, with GAAP diluted EPS up 19% and non-GAAP diluted EPS up 36%. The company maintained adequate liquidity, although cash and equivalents decreased due to significant capital deployments for acquisitions and share repurchases.

Cardinal Health, Inc. (CAH) has filed a Form 8-K on February 5, 2026, to report its financial results for the second quarter ended December 31, 2025. The filing primarily references a press release (Exhibit 99.1) containing these results, making the detailed financial performance available to investors. The company also announced an upcoming webcast to discuss these quarterly results and provide an updated outlook for the fiscal year ending June 30, 2026, with management commentary from the CEO and CFO. The presentation materials for this webcast will be accessible on the company's investor relations website.

Cardinal Health, Inc. (CAH) has filed a Form 8-K on January 13, 2026, primarily to provide an update to its previously issued fiscal year 2026 non-GAAP earnings per share (EPS) outlook. While the specific details of the updated outlook are not included in the 8-K itself, the filing indicates that this information was disclosed in a press release issued on the same date. Investors should note that Cardinal Health will also be participating in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. This conference appearance often serves as a platform for management to provide further color on business performance, strategic initiatives, and financial guidance. The press release, attached as an exhibit, is the primary source for the updated EPS outlook and any other material information shared.

Cardinal Health, Inc. (CAH) has filed an 8-K reporting the results of its 2025 Annual Meeting of Shareholders, held on November 5, 2025. The meeting primarily focused on shareholder votes concerning the Board of Directors, executive compensation, and the ratification of the independent auditor. All 12 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and strategic direction. The company also received a positive advisory vote on executive compensation, reflecting shareholder approval of the compensation packages for its named executive officers. Furthermore, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor for the upcoming fiscal year. This outcome suggests a stable governance environment and continued support for the company's financial oversight. Investors should view these results as indicators of continued operational and strategic stability within Cardinal Health.

Cardinal Health, Inc. (CAH) has filed an 8-K report on October 29, 2025, detailing its financial results for the quarter ended September 30, 2025. The company issued a press release on October 30, 2025, to announce these results, which is included as an exhibit to this filing. This report serves as the primary source for investors to understand the company's recent performance. Furthermore, Cardinal Health is scheduled to hold a webcast on October 30, 2025, where its CEO and CFO will discuss the first-quarter results and provide an outlook for the fiscal year ending June 30, 2026. The accompanying presentation slides and an audio replay of the webcast will be made available on the company's investor relations website, offering additional insights and context for shareholders and potential investors.

Cardinal Health Inc. reported a strong first quarter of fiscal year 2026, with total revenue climbing 22% year-over-year to $64.0 billion. This growth was primarily driven by a significant increase in pharmaceutical and specialty solutions sales, fueled by both existing and new customers, alongside contributions from strategic acquisitions. Non-GAAP operating earnings saw a substantial 37% increase, reflecting improved profitability from recent MSO platform acquisitions and strong performance in branded and specialty pharmaceuticals. The company announced a significant move with the agreement to acquire Solaris Health for approximately $1.9 billion, a strategic expansion into the urology MSO space. While this acquisition will be financed through debt and cash, it underscores Cardinal Health's commitment to expanding its specialized healthcare services. Despite increased interest expenses related to new debt financing, the company's diluted EPS also showed healthy growth, with non-GAAP diluted EPS increasing by 36%.

Cardinal Health, Inc. (CAH) has entered into a new 364-Day Credit Agreement, effective October 7, 2025, replacing its prior agreement. This new facility provides the company with access to $1.0 billion in revolving credit, extending through October 6, 2026. This ensures continued financial flexibility for general corporate purposes and supports its commercial paper program. A key feature allows for the potential conversion of outstanding loans into non-revolving term loans, payable one year after the agreement's termination date, offering further flexibility in managing its debt obligations.

Cardinal Health Inc. (CAH) has filed an 8-K report detailing a significant amendment to its receivables financing agreement. On September 30, 2025, Cardinal Health Funding, LLC, along with its subsidiaries and various financial institutions including Wells Fargo Bank, N.A., Liberty Street Funding LLC, The Bank of Nova Scotia, PNC Bank, National Association, Bank of America, National Association, Victory Receivables Corporation, and MUFG Bank, LTD, entered into a First Amendment to their Fifth Amended and Restated Receivables Purchase Agreement, originally dated September 1, 2023. The primary objective and impact of this amendment is to extend the maturity date of the existing receivables financing facility. The agreement's term has been successfully extended to September 28, 2028. This extension provides continued access to a crucial source of funding for the company's operations, offering financial stability and flexibility over the next three years. Investors can view the full details of this amendment as Exhibit 10.1 to the filing.

Cardinal Health, Inc. (CAH) has announced the completion of a significant public offering, raising a total of $1.0 billion through the issuance of new debt. This includes $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035. The primary purpose of this debt issuance is to fund a portion of the consideration and associated expenses for its proposed acquisition of Solaris Health. This strategic move indicates Cardinal Health's commitment to expanding its operations through acquisition. Investors should note the terms associated with this debt. The proceeds are not held in escrow and are available for general corporate purposes pending the closing of the Solaris Health acquisition. However, a critical contingency exists: if the acquisition does not close by August 12, 2026, or if Cardinal Health decides not to proceed with it, the company is obligated to redeem all issued Notes at a premium (101% of principal plus accrued interest). This special mandatory redemption provision acts as a safeguard for noteholders, ensuring their investment is protected in the event the acquisition fails to materialize.

Cardinal Health, Inc. (CAH) announced on August 13, 2025, that it has entered into an underwriting agreement to issue and sell a significant amount of senior notes. This offering comprises $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035, totaling $1 billion in aggregate principal. The issuance is being conducted under a previously effective registration statement filed with the SEC. This debt financing represents a strategic move by Cardinal Health to potentially fund its operations, investments, or refinance existing debt. Investors should note the coupon rates and maturity dates of these new notes, which provide insights into the company's cost of capital and its long-term financial strategy. The aggregate size of the offering indicates a substantial capital raise, and the specific terms will be detailed in the filed underwriting agreement.

Cardinal Health, Inc. reported a decline in total revenue for fiscal year 2025 to $222.6 billion, a 2% decrease attributed primarily to the expiration of significant contracts with OptumRx. Despite the revenue dip, both GAAP and non-GAAP operating earnings saw substantial increases, with GAAP operating earnings up 83% to $2.3 billion and non-GAAP operating earnings rising 15% to $2.8 billion. This improvement was driven by strong performance in branded and specialty pharmaceuticals, as well as contributions from recent strategic acquisitions, including those in the managed services organization (MSO) space and in-home solutions. The company actively deployed capital in fiscal 2025, with $5.3 billion allocated to acquisitions, $765 million for share repurchases, and $400 million for debt repayment. Additionally, Cardinal Health returned $494 million to shareholders through dividends. Significant acquisitions like GI Alliance, Integrated Oncology Network, and Advanced Diabetes Supply Group are expected to contribute to future growth, although they also increased amortization and acquisition-related costs. The company maintained a strong liquidity position with $3.9 billion in cash and equivalents at the end of the fiscal year.

Cardinal Health, Inc. (CAH) has filed an 8-K report detailing its financial results for the fourth quarter and full fiscal year ended June 30, 2025. The company announced these results via a press release on August 12, 2025, which is attached as an exhibit. Investors can expect a deeper dive into these results and the company's outlook for the upcoming fiscal year ending June 30, 2026, during an investor webcast scheduled for August 12, 2025, featuring the CEO and CFO. The accompanying slide presentation and audio replay will be available on the company's investor relations website. In addition to the financial results, the 8-K also discloses a significant strategic move: Cardinal Health's multi-specialty MSO, The Specialty Alliance, has entered into a definitive agreement to acquire Solaris Health. This acquisition, also announced via press release, represents a notable development for the company's business operations and future growth strategy, and further details are expected to be discussed during the webcast.

Cardinal Health, Inc. (CAH) has filed an 8-K report detailing significant updates presented at their Investor Day on June 12, 2025. The company announced its revised fiscal year 2025 outlook, alongside a preliminary outlook for fiscal year 2026. This forward-looking guidance is crucial for investors seeking to understand the company's near-term performance expectations and its strategic direction over the next 18-24 months. In addition to financial projections, Cardinal Health also provided updates on its long-term financial targets and strategic initiatives. These broader updates are designed to provide a clearer picture of the company's growth strategy, operational improvements, and capital allocation priorities. Investors should pay close attention to these strategic disclosures as they may indicate potential shifts in business focus or investment in key growth areas. The Investor Day webcast and presentation are available on the company's Investor Relations website for detailed review.

Cardinal Health, Inc. (CAH) has filed an 8-K report on May 1, 2025, disclosing its financial results for the third quarter ended March 31, 2025. The report primarily serves to announce the release of their earnings via a press release, which is attached as an exhibit. Investors should note that the detailed financial performance, including revenue, profitability, and any significant variances, will be found within the referenced news release (Exhibit 99.1).

Cardinal Health Inc. reported its third-quarter fiscal year 2025 results, demonstrating resilience despite revenue being flat year-over-year at $54.9 billion. This stability was achieved despite the prior-year impact of the OptumRx contract expiration, which was offset by growth in branded and specialty pharmaceutical sales. The company saw a significant increase in GAAP operating earnings, up 98% to $730 million, and a 21% increase in non-GAAP operating earnings to $807 million, driven by contributions from branded/specialty pharmaceuticals, cost savings initiatives, and MSO acquisitions. These improvements were partially tempered by the ongoing impact of the OptumRx contract expiration. Key strategic developments include substantial acquisitions in the healthcare services space, notably the $2.8 billion acquisition of GI Alliance (GIA) and the $1.1 billion acquisition of Advanced Diabetes Supply Group (ADSG), which are expected to bolster the Pharma and Other segments, respectively. While these acquisitions increase debt and acquisition-related costs, they signal a clear strategy to expand into higher-growth areas. The company's liquidity remains strong, supported by operating cash flow and credit facilities, though long-term debt has increased to fund these strategic investments. Investors should monitor the integration of these acquisitions and the continued impact of the OptumRx contract loss on future performance.

Cardinal Health, Inc. (CAH) announced a significant expansion of its Board of Directors with the immediate election of two new independent directors, Robert W. Musslewhite and Sudhakar Ramakrishna, effective March 7, 2025. Both individuals bring extensive leadership experience from the technology and healthcare sectors. Mr. Musslewhite, former CEO of Definitive Healthcare Corp., and Mr. Ramakrishna, CEO of SolarWinds Corporation, have been appointed to key board committees, including Audit, Human Resources and Compensation, and Risk Oversight. Their appointments are expected to enhance the board's expertise and strategic oversight.

Cardinal Health, Inc. (CAH) filed an 8-K on January 30, 2025, to announce its financial results for the second quarter ended December 31, 2024. The core of this filing revolves around the accompanying news release, which contains the detailed financial performance and operational updates for the period. Investors should refer to this news release, attached as Exhibit 99.1, for the specific figures and commentary regarding revenue, profitability, and any significant business developments. Furthermore, the company has scheduled a webcast for January 30, 2025, where the CEO and CFO will provide further insights into the quarter's performance and discuss the outlook for the fiscal year ending June 30, 2025. This event, along with the slide presentation and audio replay, will be accessible through the company's investor relations website, offering a platform for deeper understanding of management's perspective on the current financial standing and future guidance.

Cardinal Health Inc. (CAH) reported its second quarter fiscal year 2025 results, showing a decrease in revenue primarily due to the expiration of OptumRx contracts. Despite this revenue headwind, both GAAP and Non-GAAP operating earnings and diluted EPS saw significant year-over-year growth. This improvement was driven by enterprise-wide cost savings measures, growth in the BioPharma Solutions segment, and contributions from specialty networks and acquisitions. The company also highlighted substantial acquisitions, including ION and GI Alliance, which are expected to contribute to future growth, alongside a pending acquisition of Advanced Diabetes Supply Group. Management remains confident in the company's liquidity and ability to fund operations and future needs. Operationally, the Pharmaceutical and Specialty Solutions segment experienced a revenue decline but showed improved segment profit, driven by branded and specialty pharmaceutical products and BioPharma Solutions growth, partially offset by the OptumRx contract impact. The Global Medical Products and Distribution segment saw modest revenue and segment profit growth. The company also addressed significant cash outflows related to opioid litigation settlements, continuing its commitment to resolve these matters. Looking ahead, Cardinal Health is actively integrating recent acquisitions and expects them to positively impact future segment revenue and profit.

Cardinal Health Inc. (CAH) has announced an upward revision to its fiscal year 2025 non-GAAP diluted earnings per share (EPS) guidance. The company now expects its non-GAAP EPS to be toward the high end of its previously stated range of $7.75 to $7.90. This positive adjustment is primarily attributed to the sustained strong performance within its Pharmaceutical and Specialty Solutions segment. Investors should note that the company will be presenting at the JP Morgan 43rd Annual Healthcare Conference on January 14, 2025, where further commentary on this update is expected. Additionally, more comprehensive details regarding fiscal year 2025 expectations will be provided during the second quarter earnings call scheduled for January 30, 2025. The company emphasizes that it does not provide forward-looking guidance on a GAAP basis due to the unavailability of certain significant financial information.

Cardinal Health, Inc. (CAH) has entered into a new $1.0 billion Term Loan Credit Agreement with Bank of America, N.A., as Administrative Agent. This new facility is designed to provide funding for the cash consideration and related expenses associated with its previously announced acquisitions of The GI Alliance Holdings, LLC and Advanced Diabetes Supply Group. The credit agreement is set to terminate on November 10, 2025, unless certain conditions related to the consummation of these acquisitions are met earlier. Once drawn, the loans will mature three years after the borrowing date, subject to acceleration under specific circumstances.

Cardinal Health, Inc. (CAH) has filed an 8-K report detailing a significant debt financing event. The company successfully completed a public offering, raising a total of $2.85 billion through the issuance of four tranches of senior notes with varying maturity dates and interest rates. These notes include $500 million in 4.700% Notes due 2026, $750 million in 5.000% Notes due 2029, $1 billion in 5.350% Notes due 2034, and $650 million in 5.750% Notes due 2054. The primary purpose of this debt issuance is to fund a portion of the consideration for two anticipated acquisitions: The GI Alliance Holdings, LLC (GIA Acquisition) and Advanced Diabetes Supply Group. This strategic move signals Cardinal Health's intent to expand its operations through targeted acquisitions. The company also disclosed that if the GIA Acquisition is not consummated by a specified date, or if the company decides not to proceed, it will be required to redeem these notes at a premium (101% of principal plus accrued interest), indicating a contingency plan tied to the success of the GIA Acquisition.

Cardinal Health, Inc. (CAH) announced on November 17, 2024, its entry into an underwriting agreement to issue a substantial amount of senior notes across various maturities. This debt offering, totaling $2.9 billion, includes notes due in 2026, 2029, 2034, and 2054 with coupon rates ranging from 4.700% to 5.750%. This move indicates the company is actively managing its capital structure and likely seeking to refinance existing debt, fund ongoing operations, or support strategic initiatives. Investors should note the significant increase in leverage this offering represents and evaluate the company's ability to service this new debt, considering its current financial health and future cash flow generation. The issuance was made under a previously effective registration statement, suggesting a well-planned financing strategy.

Cardinal Health, Inc. (CAH) has announced a significant strategic move with the entry into an Agreement and Plan of Merger to acquire approximately 71% of The GI Alliance Holdings, LLC (GIA) for approximately $2.8 billion. This acquisition, expected to close subject to regulatory approval and customary conditions, marks a substantial investment aimed at expanding Cardinal Health's presence in the gastroenterology market. The company has secured committed financing for the transaction through a $2.9 billion senior unsecured bridge term loan facility from Bank of America, N.A. This provides flexibility for the acquisition and related expenses. Additionally, Cardinal Health has included a call option in the merger agreement to acquire the remaining outstanding equity of GIA in the future, signaling a long-term commitment to this strategic venture.

Cardinal Health, Inc. (CAH) filed an 8-K report detailing the results of its 2024 Annual Meeting of Shareholders, held on November 6, 2024. The primary focus of the filing is the outcome of four key proposals voted upon by shareholders. Notably, all ten director nominees were elected to the board, indicating strong shareholder confidence in the current leadership and governance structure. Shareholders also approved, on a non-binding advisory basis, the compensation of the company's named executive officers, often referred to as the 'say-on-pay' vote, with a majority in favor. The ratification of Ernst & Young LLP as the independent auditor for the upcoming fiscal year also received overwhelming support. However, a shareholder proposal aimed at prohibiting the re-nomination of directors who fail to receive a majority vote was not approved, suggesting a preference among shareholders for the current director nomination and election process. Overall, the filing shows positive shareholder sentiment towards board composition, executive compensation, and auditor selection, while indicating a rejection of a specific governance change proposal.

Cardinal Health Inc. (CAH) reported its first quarter fiscal year 2025 results, demonstrating resilience and strategic execution despite the significant impact of the OptumRx contract expiration. While consolidated revenue saw a 4% decrease to $52.3 billion, primarily due to the OptumRx contract loss, the company achieved a 12% increase in non-GAAP operating earnings to $625 million, driven by strong performance in branded and specialty pharmaceuticals, including the favorable impact of early COVID-19 vaccine distribution. Operationally, the company navigated the loss of OptumRx revenue by focusing on growth from existing customers and cost-saving measures. The acquisition of Integrated Oncology Network (ION) for $1.1 billion was announced, signaling a strategic move to expand its oncology services. Despite a net cash used in operating activities of $1.6 billion, largely due to working capital unwinding from OptumRx and opioid settlement payments, Cardinal Health maintained a solid liquidity position and continued its capital deployment strategy through share repurchases and dividend payments.

Cardinal Health, Inc. (CAH) has filed a Form 8-K to report its financial results for the first quarter ended September 30, 2024. The primary purpose of this filing is to disseminate information regarding the company's performance, which was announced via a press release included as an exhibit. Investors should refer to this press release for detailed financial figures and operational commentary.

Cardinal Health Inc. (CAH) has entered into a new 364-Day Credit Agreement, securing access to a $1.0 billion revolving credit facility maturing on October 7, 2025. This facility is intended for general corporate purposes and will back the company's commercial paper program. The agreement includes standard covenants, with a key financial covenant requiring a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00. Additionally, the company has amended its Issuing and Paying Agency Agreement to increase the maximum principal amount of commercial paper notes outstanding from $2.0 billion to $3.0 billion. These actions indicate a proactive approach to managing liquidity and financing needs.

Cardinal Health, Inc. (CAH) filed an 8-K report announcing the decision of two Board of Directors members, Steven K. Barg and Sujatha Chandrasekaran, not to stand for re-election at the upcoming 2024 annual shareholder meeting. Both directors, who joined the board in 2022 as part of a cooperation agreement with Elliott Associates, will continue their service until the meeting concludes. Their departure is stated to be unrelated to any disagreements with the company's operations or policies. Mr. Barg served on the now-sunsetted Business Review Committee and currently sits on the Governance and Sustainability Committee, while Ms. Chandrasekaran is a member of the Audit and Risk Oversight Committees. The company expressed gratitude for their contributions during their tenure.

Cardinal Health, Inc. reported strong revenue growth of 11% to $226.8 billion for fiscal year 2024, driven primarily by its Pharmaceutical and Specialty Solutions segment. Despite this top-line expansion, the company experienced a significant goodwill impairment charge of $675 million related to its Global Medical Products and Distribution (GMPD) segment, which fully impaired the goodwill for that segment. Non-GAAP diluted EPS showed substantial growth, increasing by 29% to $7.53, reflecting improved operational performance excluding these non-recurring charges. The company also announced the expiration of its pharmaceutical distribution contracts with OptumRx at the end of June 2024, which is expected to negatively impact fiscal 2025 results. However, the recent acquisition of Specialty Networks for $1.2 billion is anticipated to bolster the Pharmaceutical and Specialty Solutions segment. Cardinal Health maintained its focus on capital deployment, returning capital to shareholders through share repurchases and dividends, while managing its debt obligations and accruing significant reserves for opioid-related litigation.

Cardinal Health, Inc. (CAH) has filed an 8-K report on August 14, 2024, detailing its financial results for the fourth quarter and full fiscal year ended June 30, 2024. The primary driver of this filing is the press release (Exhibit 99.1) announcing these results, which provides investors with the latest performance figures. The company also announced that its CEO and CFO will discuss these results, along with the outlook for the fiscal year ending June 30, 2025, during a webcast scheduled for August 14, 2024. The presentation slides and an audio replay of the webcast will be made available on the company's investor relations website.

Cardinal Health Inc. reported solid revenue growth in the third quarter of fiscal year 2024, with total revenue increasing by 9% year-over-year to $54.9 billion. This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical and Specialty Solutions segment. While GAAP operating earnings saw a decline primarily due to litigation charges and goodwill impairment, the company's non-GAAP operating earnings showed significant improvement, increasing by 10% to $666 million. This highlights the company's operational performance excluding certain non-recurring or significant charges. Despite ongoing challenges, including significant litigation expenses and a goodwill impairment charge related to the GMPD segment, Cardinal Health demonstrated strong operational execution. The company's strategic acquisition of Specialty Networks for $1.2 billion aims to enhance its data analytics capabilities and expand its offerings in key therapeutic areas. However, investors should note the upcoming non-renewal of contracts with OptumRx, which represented 16% of fiscal year 2023 revenue, posing a significant headwind for fiscal year 2025. The company is actively managing its capital through share repurchases and dividends while maintaining adequate liquidity.

Cardinal Health, Inc. (CAH) filed an 8-K on May 2, 2024, primarily to announce its financial results for the third quarter ended March 31, 2024. The filing references a press release (Exhibit 99.1) that contains the detailed financial performance for the quarter. Investors should refer to this press release for specific figures regarding revenue, earnings, and other key financial metrics. Furthermore, the report indicates that management will host a webcast on May 2, 2024, to discuss these results, provide an updated outlook for the full fiscal year ending June 30, 2024, and offer a preliminary outlook for the fiscal year ending June 30, 2025. The slide presentation and an audio replay of this webcast will be made available on the company's investor relations website, providing crucial forward-looking information and context for investors.

Cardinal Health Inc. (CAH) has filed an 8-K report detailing a voluntary restructuring of its operating and reporting segments, effective from the third quarter of fiscal year 2024. This initiative aims to simplify the company's structure, enhance operational focus, and improve accountability and transparency. Investors should note that this filing provides unaudited, recast segment results for fiscal years 2022 and 2023, as well as the first two quarters of fiscal year 2024, under this new framework. The company has consolidated its reporting into two primary segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. Three smaller operating segments—Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics—will be reported collectively under 'Other.' Importantly, these recast results do not alter previously reported consolidated financial figures like revenue, operating earnings, net earnings, or EPS. The changes primarily affect how inter-segment revenues and allocated corporate expenses are treated within the new reporting structure.

Cardinal Health, Inc. (CAH) has filed an 8-K report on April 22, 2024, to disclose a significant business development: the non-renewal of its pharmaceutical distribution contracts with OptumRx. This announcement, made via a press release, signals a substantial shift in Cardinal Health's customer relationships and could have implications for its future revenue streams and market position within the pharmaceutical distribution segment. Investors should pay close attention to the potential impact of losing a major client like OptumRx. While the specifics of the non-renewal terms and the timeline are not detailed in this 8-K, the event warrants a closer look at Cardinal Health's customer concentration, its strategies for mitigating the financial impact, and its overall outlook for the pharmaceutical distribution business. This development could also influence investor sentiment and necessitate a review of the company's long-term growth prospects.

Cardinal Health, Inc. (CAH) announced a key board appointment in its recent 8-K filing. Robert W. Azelby has been elected to the Board of Directors, effective March 1, 2024. Mr. Azelby brings a background as the former President and Chief Executive Officer of Eliem Therapeutics, Inc., a biotechnology firm. His appointment is expected to enhance the Board's expertise, particularly with his inclusion on the Risk Oversight Committee. This appointment is effective until the upcoming 2024 annual shareholder meeting. The company confirmed that Mr. Azelby meets the independence requirements set by the NYSE and SEC. His compensation will align with that of other non-employee directors. This move suggests a continued focus on strengthening board governance and risk management as the company navigates its strategic objectives.

Cardinal Health, Inc. (CAH) has filed an 8-K report detailing a significant financing event. On February 20, 2024, the company successfully completed a public offering of new debt securities, raising a total of $1.15 billion. This offering consisted of $650 million in 5.125% Notes due in 2029 and $500 million in 5.450% Notes due in 2034. The issuance of these notes represents a material definitive agreement and the creation of a direct financial obligation for the company. The proceeds from this offering are expected to be used for general corporate purposes. This action signals the company's ongoing strategy to manage its capital structure and fund its operations.

Cardinal Health Inc. (CAH) reported a strong second quarter for fiscal year 2024, with total revenue increasing by 12% year-over-year to $57.4 billion. This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical segment. The company also demonstrated significant improvements in profitability, with non-GAAP operating earnings up 20% and non-GAAP diluted EPS rising 38% year-over-year. This enhanced performance is attributed to stronger contributions from both the Pharmaceutical and Medical segments. Looking ahead, Cardinal Health announced a significant strategic move with the definitive agreement to acquire Specialty Networks for $1.2 billion in cash. This acquisition is expected to bolster the company's offerings in key therapeutic areas by enhancing analytics capabilities and accelerating data and research opportunities with biopharma manufacturers. The company also maintains a healthy liquidity position, with cash and equivalents increasing to $4.6 billion, supported by robust operating cash flow, and continues its capital return strategy through share repurchases and dividends.

Cardinal Health, Inc. (CAH) has filed an 8-K report on February 1, 2024, primarily announcing its financial results for the second quarter ended December 31, 2023. The report includes a press release detailing these results, which are also being discussed by company leadership during a webcast on February 1, 2024. Investors should refer to the press release (Exhibit 99.1) for specific financial figures and operational performance details for the quarter. The company is also providing an outlook for the fiscal year ending June 30, 2024, during the aforementioned webcast. This forward-looking information is crucial for investors assessing the company's future performance and strategic direction. Both the webcast presentation slides and an audio replay will be made available on the company's investor relations website, ir.cardinalhealth.com, allowing investors to access these key updates.

Cardinal Health, Inc. (CAH) has filed an 8-K report on January 9, 2024, to announce significant updates regarding its business and financial outlook. The company is providing an updated enterprise operating and segment reporting structure as part of an ongoing business and portfolio review. This structural change signals a strategic re-evaluation aimed at optimizing performance and potentially streamlining operations. Investors should pay close attention to how this new structure impacts future segment performance and overall company strategy. Furthermore, Cardinal Health has revised its fiscal year 2024 non-GAAP diluted earnings per share (EPS) outlook upwards. This upward revision suggests management's increased confidence in the company's ability to achieve its financial targets for the year. Additionally, the company provided an update on its Medical segment profit expectations for the quarter ending December 31, 2023, indicating potential strength or positive developments within this specific business unit. These announcements were made via a press release, and management is hosting a conference call to discuss these developments further.

Cardinal Health, Inc. (CAH) filed an 8-K on November 16, 2023, reporting the results of its Annual Meeting of Shareholders held on November 15, 2023. The primary focus of this filing is the outcome of six proposals voted upon by shareholders. Investors will be interested to note that all director nominees were elected, and the company's appointment of Ernst & Young LLP as its independent auditor for fiscal year 2024 was ratified with overwhelming support. Additionally, shareholders approved the executive compensation on an advisory basis (say-on-pay) and supported holding such votes annually. However, two shareholder proposals did not pass: one seeking a policy for executive stock retention and another for shareholder ratification of excessive termination pay. These outcomes suggest that while shareholders are generally aligned with the board's composition and compensation practices, they rejected specific proposals aimed at increasing executive accountability through stock retention and termination pay oversight. The high number of broker non-votes on most proposals indicates that a significant portion of shares held in 'street name' did not have voting instructions from the beneficial owners for these particular items.

Cardinal Health Inc. reported robust revenue growth in its first quarter of fiscal year 2024, with total revenue increasing by 10% to $54.8 billion, primarily driven by strong performance in its Pharmaceutical segment. This growth was fueled by increased branded and specialty pharmaceutical sales, as well as the early distribution of COVID-19 vaccines. The company also saw a significant improvement in Non-GAAP operating earnings, which rose 35% to $571 million, and Non-GAAP diluted EPS increased by 44% to $1.73, reflecting improved segment profitability and a lower share count due to repurchases. Despite overall positive operational trends, GAAP operating earnings showed a loss of $14 million due to a substantial $581 million goodwill impairment charge related to the Medical segment. While this impairment impacts GAAP figures, the company's Non-GAAP performance highlights underlying operational strength. Cardinal Health continues to manage its liquidity effectively, with $3.9 billion in cash and equivalents and a strong credit facility. The company is also actively returning capital to shareholders through dividends and share repurchases, with $3.8 billion remaining on its share repurchase authorization.

Cardinal Health, Inc. (CAH) filed an 8-K on November 3, 2023, to announce its financial results for the first quarter ended September 30, 2023. The company released its earnings through a press release, which is attached as an exhibit. This filing serves as a primary source for investors seeking the latest financial performance data and management's commentary on the company's trajectory. Investors can expect further details and forward-looking statements during a webcast scheduled for November 3, 2023, featuring the CEO and CFO. This webcast will cover the first-quarter results and provide an outlook for the fiscal year ending June 30, 2024. Presentation materials and an audio replay will be accessible on the company's investor relations website.

Cardinal Health Inc. (CAH) announced a significant amendment and restatement to its receivables purchase agreement on September 1, 2023. This strategic move involves adding a new subsidiary, Cardinal Health 23 Funding, LLC (CH-23 Funding), as an additional seller of receivables under its $1.0 billion committed receivables sales facility. Furthermore, the company has appointed another subsidiary, Cardinal Health 23, LLC (CH-23), as the new servicer for this facility, replacing Griffin Capital. These changes are expected to enhance the efficiency and structure of Cardinal Health's receivables financing operations. In conjunction with this amendment, the Company has also entered into a Performance Guaranty to back the obligations of its affiliated originators and CH-23 as the servicer. This guaranty includes compliance with certain financial covenants, indicating a commitment to the new servicing arrangement and the overall financial health of the program. Investors should view this as a procedural update aimed at optimizing the company's financing capabilities.

Cardinal Health, Inc. reported a significant increase in revenue for fiscal year 2023, reaching $205.0 billion, driven primarily by its Pharmaceutical segment. The company's consolidated GAAP operating earnings improved to $727 million from a loss of $596 million in the prior year, largely benefiting from litigation recoveries. On a non-GAAP basis, operating earnings increased by 3% to $2.1 billion, reflecting growth in the Pharmaceutical segment's profit, partially offset by a decline in the Medical segment's profit. The company faced challenges in its Medical segment, which saw a 5% decrease in revenue due to lower volumes and unfavorable product mix, compounded by ongoing inflationary impacts. Significant goodwill impairment charges totaling $1.2 billion were recognized in the Medical segment during fiscal 2023, following a $2.1 billion charge in fiscal 2022, reflecting revised long-term financial plan assumptions. The company continues to manage substantial long-term liabilities, including a significant accrual for opioid litigation, with payments expected through 2038. Financially, Cardinal Health returned $2.0 billion to shareholders through share repurchases and paid $525 million in dividends in fiscal 2023. The company maintained a strong liquidity position, with cash and equivalents of $4.0 billion at year-end. Looking ahead, the company expects continued inflationary impacts in the Medical segment, albeit at a reduced level, and anticipates sales growth in its branded medical products.

Cardinal Health Inc. (CAH) filed an 8-K on August 14, 2023, detailing its financial results for the quarter and fiscal year ended June 30, 2023. The company announced these results via a press release filed as Exhibit 99.1. This report also disclosed the upcoming departure of a long-standing Board member, Carrie S. Cox, who will not seek re-election at the upcoming shareholder meeting, citing no disagreements with the company. Furthermore, the 8-K announced a webcast scheduled for August 15, 2023, where the CEO and CFO would discuss the recently reported financial performance and provide an outlook for the fiscal year ending June 30, 2024. Investors are encouraged to review the press release and the webcast presentation for detailed financial information and future guidance.

Cardinal Health, Inc. (CAH) filed an 8-K on June 8, 2023, to announce significant updates regarding its financial outlook and strategic direction, as detailed in a press release furnished as an exhibit. The company provided an updated outlook for fiscal year 2023 and a preliminary outlook for fiscal year 2024. Investors should note the introduction of long-term financial targets and an updated capital allocation framework, which signal a renewed focus on shareholder value and disciplined financial management. These announcements were made in conjunction with an Investor Day event where management further elaborated on growth strategies and ongoing business reviews.

Cardinal Health, Inc. (CAH) filed an 8-K on May 11, 2023, primarily to announce an amendment and restatement of its Code of Regulations, effective immediately. The core purpose of these amendments is to align the Company's procedures with the U.S. Securities and Exchange Commission's (SEC) new "universal proxy" rules (Rule 14a-19). This update is crucial for shareholders intending to nominate directors for consideration at the company's meetings.

Cardinal Health Inc. (CAH) filed an 8-K on May 4, 2023, primarily related to the extension of a cooperation agreement with Elliott Associates, L.P. and its affiliates. This amendment to the September 2022 agreement extends its term until at least July 15, 2024, and also extends the term of the Company's Business Review Committee. This suggests continued engagement and a potentially longer-term strategic dialogue between the Company and Elliott. The filing also serves as a notification of the Company's financial results for the quarter ended March 31, 2023, which were released via a press announcement on May 4, 2023. While the 8-K itself doesn't detail these results, it directs investors to the press release (Exhibit 99.1) and upcoming investor webcast scheduled for May 4, 2023, where management will discuss the quarterly performance and provide an updated outlook for the fiscal year ending June 30, 2023. Investors should review these related materials for specific financial performance details.

Cardinal Health Inc. reported solid revenue growth in the third quarter of fiscal year 2023, with a 13% increase year-over-year, driven primarily by strong performance in its Pharmaceutical segment, particularly from branded and specialty pharmaceutical sales. The company also saw a significant improvement in GAAP operating earnings, shifting from a loss in the prior year to a gain, largely due to favorable litigation recoveries and the absence of prior-year goodwill impairment charges in the Medical segment. Non-GAAP operating earnings saw an 11% increase for the quarter, also bolstered by the Pharmaceutical segment. Despite the top-line growth and improved operating earnings, the Medical segment experienced a revenue decline due to lower volumes and pricing in personal protective equipment (PPE), though segment profit was positively impacted by lower PPE costs. The company continues to navigate inflationary pressures, which had a mixed impact across segments. Cardinal Health also actively managed its capital, repurchasing $1.5 billion in shares and paying $399 million in dividends during the nine-month period. The company maintains adequate liquidity and is managing its significant opioid litigation settlement obligations, with a substantial portion of the payments scheduled over the next 17 years.

Cardinal Health, Inc. (CAH) filed an 8-K on March 1, 2023, detailing a significant update to its financing structure. The company entered into a Third Amended and Restated Five-Year Credit Agreement, which provides access to a $2.0 billion revolving credit facility and extends its term to February 25, 2028. This refinancing enhances the company's financial flexibility and liquidity. The agreement includes customary covenants, with a key financial covenant requiring a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00. Notably, the new credit agreement incorporates provisions for Environmental, Social, and Governance (ESG) targets, allowing for potential adjustments to facility fees and margins based on performance. This demonstrates Cardinal Health's commitment to integrating ESG considerations into its financing. The facility backs the company's commercial paper program and is available for general corporate purposes, underscoring its importance for ongoing operational needs.